Sei Investments Co. Buys 31,600 Shares of Zoetis Inc. (NYSE:ZTS)

Sei Investments Co. raised its stake in Zoetis Inc. (NYSE:ZTS) by 8.5% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 401,669 shares of the company’s stock after purchasing an additional 31,600 shares during the period. Sei Investments Co. owned 0.09% of Zoetis worth $69,633,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in ZTS. Vanguard Group Inc. increased its holdings in shares of Zoetis by 1.0% during the first quarter. Vanguard Group Inc. now owns 40,749,571 shares of the company’s stock valued at $6,895,235,000 after acquiring an additional 414,605 shares in the last quarter. Price T Rowe Associates Inc. MD increased its stake in Zoetis by 31.0% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 13,716,681 shares of the company’s stock valued at $2,707,262,000 after purchasing an additional 3,244,074 shares in the last quarter. Capital World Investors raised its holdings in Zoetis by 0.6% during the fourth quarter. Capital World Investors now owns 9,064,158 shares of the company’s stock worth $1,788,988,000 after buying an additional 57,798 shares during the last quarter. Bank of New York Mellon Corp raised its holdings in Zoetis by 4.0% during the second quarter. Bank of New York Mellon Corp now owns 4,687,902 shares of the company’s stock worth $812,695,000 after buying an additional 178,303 shares during the last quarter. Finally, Capital Research Global Investors grew its holdings in shares of Zoetis by 2.3% during the first quarter. Capital Research Global Investors now owns 4,050,681 shares of the company’s stock valued at $685,416,000 after buying an additional 90,330 shares during the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Stock Down 0.3 %

Zoetis stock opened at $192.64 on Friday. The company has a quick ratio of 2.09, a current ratio of 3.45 and a debt-to-equity ratio of 1.32. The company has a market capitalization of $87.90 billion, a P/E ratio of 37.12, a P/E/G ratio of 2.98 and a beta of 0.88. The firm has a 50 day moving average price of $184.70 and a 200-day moving average price of $174.40. Zoetis Inc. has a twelve month low of $144.80 and a twelve month high of $201.92.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Tuesday, August 6th. The company reported $1.56 earnings per share for the quarter, beating the consensus estimate of $1.49 by $0.07. Zoetis had a return on equity of 50.67% and a net margin of 26.29%. The firm had revenue of $2.36 billion for the quarter, compared to analysts’ expectations of $2.31 billion. During the same period in the prior year, the business posted $1.41 earnings per share. The company’s revenue was up 8.3% on a year-over-year basis. As a group, equities analysts predict that Zoetis Inc. will post 5.84 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on ZTS shares. BTIG Research upped their target price on shares of Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a report on Monday, August 12th. Argus upgraded Zoetis to a “strong-buy” rating in a report on Friday, August 9th. Stifel Nicolaus upped their price target on Zoetis from $200.00 to $210.00 and gave the stock a “buy” rating in a report on Wednesday. Finally, Piper Sandler raised their price objective on Zoetis from $195.00 to $210.00 and gave the company an “overweight” rating in a research note on Wednesday, August 14th. Nine investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $220.38.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.